On Demand

Why vaccinate HIV positive adults?

Frances Chatham

Overview: This short video features lead practice nurse and trainer Frances Chatham talking about the British HIV Association (BHIVA) vaccination recommendation for Prevenar 13 (PCV 13).

On Demand

British HIV Association (BHIVA) Access and Re-imbursement

Frances Chatham

Overview: This short video features lead practice nurse and trainer Frances Chatham talking about access and reimbursement for Prevenar 13 (PCV13) associated with the BHIVA vaccination recommendation for PCV13. 

Considerations when selecting a treatment for 2nd line mRCC patients
On Demand

Considerations when selecting a 2nd line treatment for mRCC patients

Various speakers

Pfizer logo for various speakers

In this video, leading mRCC experts provide their views on how to select a 2nd line treatment for their mRCC patients. This interview was recorded on 23 June 2017.

Treatment selection in 2nd line mRCC
On Demand

Treatment selection in 2nd line mRCC

Dr Enrique Grande

Dr Enrique Grande

In this interview, Dr Enrique Grande provides his approach to treatment selection in 2nd line mRCC. In particular, he describes how he would use Inlyta in favourable risk patients and patients who had a long-lasting clinical benefit to a TKI in the 1st line setting. This interview was recorded on the 23 June 2017.

Patients most likely to benefit from axitinib
On Demand

Which patients are most likely to benefit from axitinib?

Various speakers

Pfizer logo for various speakers

In this video, leading mRCC experts provide their views on which patients are most likely to benefit from Inlyta in 2nd line mRCC. This interview was recorded on the 23 June 2017.

On Demand

Prof Roy Fleischmann: ORAL Strategy trial

Prof Fleischmann

Professor Fleischmann's summary of the methodology of the ORAL Strategy trial and presentation of the results.

On Demand

Prof Rieke Alten: Unmet needs and patient reported outcomes

Prof Alten

Professor Alten discusses the state of unmet needs of rheumatoid arthitis sufferers, and the patient-reported outcomes from the tofacitinib phase III trials.

On Demand

Dr Peter Nash: long term safety data

Dr Nash

Dr Nash provides insights into the XELJANZ Mode of Action, key patient clinical measures used in his daily practice and the important patient outcomes that are focused on.

On Demand

Prof Janet Pope: reaction to Xeljanz symposium

Prof Pope

Professor Pope discusses the key take home messages on the latest JAK inhibitor data from the Pfizer RA symposium at EULAR, and the implications this data has for clinical management of RA patients.

On Demand

Dr Eduardo Mysler: onset of action and sustained efficacy

Dr Mysler

Dr Eduardo Mysler discusses the onset of action and sustained efficacy